BRAF and melanoma: For example, one tier would consist experimentally validated driver combinations, such as BRAF + PTEN in melanomas and ATRX + IDH1 + TP53 in gliomas, and lower tiers would consist of computationally predicted combinations nominated by methods such as CRSO and SELECT, with varying amount of literature support.